BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 21, 2004
View Archived Issues
OSI's Prosidion Buying Diabetes Drug, Assets For At Least $35M
OSI Pharmaceuticals Inc. is acquiring substantially all the assets of one of its subsidiaries, Prosidion Ltd., in connection with the latter's purchase of a Phase II diabetes drug and related technology. (BioWorld Today)
Read More
With Poor Data, Inflazyme To Drop LSAID In Asthma
Read More
FBI: Biotech Industry Not Facing Serious Problem' Of Extremists
Read More
After Reagan's Death, Pressure Mounts For Human ESC Reform
Read More
Guilford Licenses GPI 1485 To New Company Symphony
Read More
Other News To Note
Read More
Clarification
Read More